EU H2020 Project "BREAK (Blue light remote analgesia with K+ channels)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/225852/index.html
-1	/open-h2020/projects/193719/deliverables.html
-2	/open-h2020/projects/212647/index.html
-3	/open-h2020/projects/195192/index.html
-4	/open-h2020/projects/195847/index.html
-5	/open-consip/fornitori/2017/profilo-01470090836/index.html
-6	/open-h2020/projects/199080/deliverables.html
-7	/open-h2020/projects/227506/index.html
-8	/open-h2020/projects/210966/index.html
-9	/open-h2020/projects/194972/index.html

BREAK project word cloud

Explore the words cloud of the BREAK project. It provides you a very rough idea of what is the project "BREAK" about.

blink2 injected centers explore stakeholder origin 12 abnormal experiments exact break medical illness entities worse patients brain silencing nausea treatments plan neuron diagnose characterised chronic originally situation prolonged investor vivo virus painful trauma constitute inhibitory proteins genes global reporting addiction extremely optical 8 adoption engineered drugs distance invasiveness lamp disorder first treatment relief tool area actually neuropathic partial commercial pharma normally blue antidepressants designed hard fruitful 20 rats minutes progress demonstrated opioids thirds leveraging hospitals optogenetic cells lower synergy stimuli invasive causing skin solution network peripheral hours genetically light population damage interpret restraining spectrum cp difficult initiated kept version pain academic treat protein np weeks despite class adults central gt drug leads nonspecific device mostly implant nervous companies cm

Project "BREAK" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITA DEGLI STUDI DI MILANO Organization address address: Via Festa Del Perdono 7 city: MILANO postcode: 20122 website: www.unimi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	0 €
EC max contribution	150˙000 € (0%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2019-PoC
Funding Scheme	ERC-POC-LS
Starting year	2019
Duration (year-month-day)	from 2019-12-01 to 2021-05-31

#	participants	country	role	EC contrib. [€]
1	UNIVERSITA DEGLI STUDI DI MILANO	IT (MILANO)	coordinator	150˙000.00

UNIVERSITA DEGLI STUDI DI MILANO

IT (MILANO)

coordinator

150˙000.00

Project objective

Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks) originally initiated by a trauma or illness. Despite significant progress, CP remains extremely hard to treat, with only one-third to two-thirds of patients reporting adequate some pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population and whose origin mostly depend on peripheral or central nervous damage or disorder, which leads the brain to interpret as pain normally non painful stimuli. NP is difficult to treat due to the large number of entities involved (cells, genes and proteins working in synergy), which makes it hard to rapidly diagnose the exact cause of pain. Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction, and nausea, thus restraining their adoption for prolonged treatments. BREAK is the first non-invasive inhibitory optogenetic tool specifically designed for NP treatment, with potential application to the whole spectrum of CP. BREAK is composed of a drug and an optical device. The protein BLINK2 is injected in the painful area using a genetically engineered virus, and respond to a specific blue light by silencing the addressed neuron. The lamp can be kept at some distance (cm) from the skin and no implant is required. Just some minutes of treatment results in hours of pain relief, making the invasiveness of BREAK far lower than actually existing solution. A first version of BREAK has already demonstrated in in-vivo experiments on rats. During this project we plan to further develop the treatment and explore its commercial potential. In particular, leveraging from the experience of different partners, we will constitute a fruitful stakeholder network, including Academic centers, hospitals, pharma companies and investor

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREAK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREAK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields